Systemic inhibition of TGF-β signaling in Smad 3–deficient mice or using an anti–TGF-β1 antibody has been reported to mitigate adverse effects of obesity and diabetes on energy metabolism (19). The gene discussed is TGFB1; the disease is obesity due to melanocortin 4 receptor deficiency.